Should we Cut Back on IVF?
By Lara Salahi,
The Boston Globe
| 01. 29. 2014
In vitro fertilization (IVF) has given about 5 percent of couples who suffer from infertility a shot at parenthood. But are we overusing the technology without clearly understanding its risks? Yes, say a group of European researchers who came to the conclusion by reviewing studies on women who underwent the procedure and the health of children born using the technology.
IVF was originally approved for use in women with fallopian tube disorders and men who suffered with infertility. Today IVF is used with couples with other types of
infertility-related disorders -- including unexplained infertility. In their analysis
published Tuesday in the British Medical Journal, the European researchers say we may be overusing IVF to treat an expanded list of conditions without clear evidence that it will be effective. Even if it does work, the procedure is performed without knowing what the risks may be for the women or IVF-born children later on.
Although it’s has been around since the late 1970s, there’s a lot we still don’t know about IVF. More than 60,000 children with born through IVF...
Related Articles
By Tomoko Otake, The Japan Times | 04.09.2024
A decade ago, researcher Haruko Obokata caused a sensation when she published two papers in the journal Nature, in which she claimed that she had discovered a way to create stem cells easily using the so-called STAP method.
With STAP...
By Yelena Biberman and Jonathan D. Moreno, Bioethics Forum | 04.16.2024
A quiet biological revolution in warfare is underway. The genome is emerging as a new domain of conflict. The level of destruction that only nuclear weapons could previously achieve is fast becoming as accessible as a cyberattack.
Now for the...
CGS is excited to announce the launch of a new anti-eugenics initiative that has been years in the making. Legacies of Eugenics in Science, Medicine, and Technology kicks off with a monthly essay series published at the Los Angeles Review of Books that will expose and contest the reemergence of eugenic ideas in contemporary health sciences, human biotechnology, public health, and medicine. Community and campus-based events featuring the authors are also being planned. The project is a collaboration among CGS...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...